Pro Exclusive: Gilead CEO on biotech valuations

John Milligan, CEO of Gilead
Victor J. Blue/ | Bloomberg | Getty Images
John Milligan, CEO of Gilead

John Milligan, president and CEO of Gilead Sciences, joined Meg Tirrell for a CNBC Pro exclusive interview to discuss the company's business strategy amid a tumultuous environment in the biotech space.

Among the topics discussed, Milligan described biotech share price valuations and the state of pharmaceutical advancements, and provided the pulse on mergers and acquisitions.

Watch the video below for all the highlights:

Contact Investing


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about our products and service. Privacy Policy.